Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366815539> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4366815539 endingPage "270" @default.
- W4366815539 startingPage "262" @default.
- W4366815539 abstract "Abstract Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been implicated as a promising potential in cancer treatment. Therefore, the present study aimed to investigate the repurposing of raltegravir as an anticancer agent and its mechanism of action in multiple myeloma (MM). Human MM cell lines (RPMI‐8226, NCI H929, and U266) and normal peripheral blood mononuclear cells (PBMCs) were cultured with different concentrations of raltegravir for 48 and 72 h. Cell viability and apoptosis were then measured by MTT and Annexin V/PI assays, respectively. Protein levels of cleaved PARP, Bcl‐2, Beclin‐1, and phosphorylation of histone H2AX were detected by Western blotting. In addition, the mRNA levels of V(D)J recombination and DNA repair genes were analyzed using qPCR. Raltegravir treatment for 72 h significantly decreased cell viability, increased apoptosis, and DNA damage in MM cells while having minimum toxicity on cell viability of normal PBMCs approximately from 200 nM (0.2 μM; p < .01 for U66 and p < .0001 for NCI H929 and RPMI 8226 cells). Furthermore, raltegravir treatment altered the mRNA levels of V(D)J recombination and DNA repair genes. We report for the first time that treatment with raltegravir is associated with decreased cell viability, apoptosis induction, DNA damage accumulation, and alteration of mRNA expression of genes involved in V(D)J recombination and DNA repair in MM cell lines, all of which show its potential for anti‐myeloma effects. Hence, raltegravir may significantly impact the treatment of MM, and further studies are required to confirm its efficacy and mechanism of action in more detail in patient‐derived myeloma cells and in‐vivo models." @default.
- W4366815539 created "2023-04-25" @default.
- W4366815539 creator A5016816660 @default.
- W4366815539 creator A5033439690 @default.
- W4366815539 creator A5049124047 @default.
- W4366815539 creator A5058144610 @default.
- W4366815539 creator A5066919098 @default.
- W4366815539 date "2023-04-24" @default.
- W4366815539 modified "2023-10-14" @default.
- W4366815539 title "<scp>HIV</scp>‐1 integrase inhibitor raltegravir promotes <scp>DNA</scp> damage‐induced apoptosis in multiple myeloma" @default.
- W4366815539 cites W2001994403 @default.
- W4366815539 cites W2085975874 @default.
- W4366815539 cites W2104617999 @default.
- W4366815539 cites W2118362719 @default.
- W4366815539 cites W2164678766 @default.
- W4366815539 cites W2620871936 @default.
- W4366815539 cites W2887036946 @default.
- W4366815539 cites W2951117603 @default.
- W4366815539 cites W2982489466 @default.
- W4366815539 cites W3130983471 @default.
- W4366815539 cites W4210289046 @default.
- W4366815539 cites W4225115378 @default.
- W4366815539 cites W4280556871 @default.
- W4366815539 cites W4286002146 @default.
- W4366815539 cites W4308364989 @default.
- W4366815539 cites W4312748575 @default.
- W4366815539 doi "https://doi.org/10.1111/cbdd.14237" @default.
- W4366815539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37094820" @default.
- W4366815539 hasPublicationYear "2023" @default.
- W4366815539 type Work @default.
- W4366815539 citedByCount "1" @default.
- W4366815539 countsByYear W43668155392023 @default.
- W4366815539 crossrefType "journal-article" @default.
- W4366815539 hasAuthorship W4366815539A5016816660 @default.
- W4366815539 hasAuthorship W4366815539A5033439690 @default.
- W4366815539 hasAuthorship W4366815539A5049124047 @default.
- W4366815539 hasAuthorship W4366815539A5058144610 @default.
- W4366815539 hasAuthorship W4366815539A5066919098 @default.
- W4366815539 hasConcept C142462285 @default.
- W4366815539 hasConcept C153911025 @default.
- W4366815539 hasConcept C159047783 @default.
- W4366815539 hasConcept C185592680 @default.
- W4366815539 hasConcept C190283241 @default.
- W4366815539 hasConcept C2522874641 @default.
- W4366815539 hasConcept C2780404665 @default.
- W4366815539 hasConcept C2993143319 @default.
- W4366815539 hasConcept C502942594 @default.
- W4366815539 hasConcept C53227056 @default.
- W4366815539 hasConcept C55493867 @default.
- W4366815539 hasConcept C86803240 @default.
- W4366815539 hasConceptScore W4366815539C142462285 @default.
- W4366815539 hasConceptScore W4366815539C153911025 @default.
- W4366815539 hasConceptScore W4366815539C159047783 @default.
- W4366815539 hasConceptScore W4366815539C185592680 @default.
- W4366815539 hasConceptScore W4366815539C190283241 @default.
- W4366815539 hasConceptScore W4366815539C2522874641 @default.
- W4366815539 hasConceptScore W4366815539C2780404665 @default.
- W4366815539 hasConceptScore W4366815539C2993143319 @default.
- W4366815539 hasConceptScore W4366815539C502942594 @default.
- W4366815539 hasConceptScore W4366815539C53227056 @default.
- W4366815539 hasConceptScore W4366815539C55493867 @default.
- W4366815539 hasConceptScore W4366815539C86803240 @default.
- W4366815539 hasFunder F4320309936 @default.
- W4366815539 hasIssue "2" @default.
- W4366815539 hasLocation W43668155391 @default.
- W4366815539 hasLocation W43668155392 @default.
- W4366815539 hasOpenAccess W4366815539 @default.
- W4366815539 hasPrimaryLocation W43668155391 @default.
- W4366815539 hasRelatedWork W1965354305 @default.
- W4366815539 hasRelatedWork W1976475396 @default.
- W4366815539 hasRelatedWork W2015807416 @default.
- W4366815539 hasRelatedWork W2050011194 @default.
- W4366815539 hasRelatedWork W2056596520 @default.
- W4366815539 hasRelatedWork W2110945650 @default.
- W4366815539 hasRelatedWork W2148544227 @default.
- W4366815539 hasRelatedWork W2163045808 @default.
- W4366815539 hasRelatedWork W2740220467 @default.
- W4366815539 hasRelatedWork W2740566981 @default.
- W4366815539 hasVolume "102" @default.
- W4366815539 isParatext "false" @default.
- W4366815539 isRetracted "false" @default.
- W4366815539 workType "article" @default.